Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 28;24(21):3876. doi: 10.3390/molecules24213876

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Changes in the levels of (A) serum creatinine, (B) blood urea nitrogen (BUN), and (C) histopathology after an intraperitoneal injection of cisplatin (20 mg/kg). Saline or eleutheroside B was injected 30 min before the injection of cisplatin. Each column represents the mean ± SD (n = 4–7). Results of serum creatinine and BUN show that treatment of eleutheroside B (20, 40, 60 mg/kg) restored renal function in cisplatin nephropathy. C: periodic acid-Schiff (PAS) staining and score. Results of PAS staining and score of severity indicate that treatment with set concentrations of eleutheroside B (20, 40, 60 mg/kg) alleviated tubular necrosis, tubular dilation, and cast formation in cisplatin nephropathy. Data are mean ± SEM for 6–8 mice. *** p < 0.001 compared to normal; ^## p < 0.01, ^### p < 0.001 compared to model. Cis, cisplatin; EB, eleutheroside B. KIM-1: kidney injury molecule-1. Magnification, 20×.